Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
Signet Therapeutics
Seed Round in 2021
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Etern is developing small molecule innovative drugs for oncology therapies.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, the company aims to address the significant morbidity and mortality associated with sleep apnea, which affects over 20 million Americans. Apnimed's approach targets the neurobiological mechanisms that lead to airway obstruction, offering a simple, orally dosed treatment option. This strategy contrasts with current therapies, which primarily rely on positive pressure devices like CPAP, as well as other less commonly used methods such as mandibular advancement devices and surgical interventions. Apnimed's therapeutics are designed to alleviate both the physiological and symptomatic effects of obstructive sleep apnea, providing a safe and effective solution that addresses the underlying biology of the condition.
PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.
New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.
Tallac Therapeutics, Inc. develops immunotherapies for cancer patients. Tallac Therapeutics, Inc. was formerly known as Tollnine, Inc. The company was founded in 2018 and is based in Burlingame, California.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Beijing Naxions Technology Co., Ltd. is a healthcare-focused company that specializes in providing digital marketing services tailored for the pharmaceutical industry. Founded in 2014 and headquartered in Chaoyang District, China, with additional offices in Shanghai, Naxions has developed a software-as-a-service (SaaS) platform designed to enhance pharmaceutical sales management. The platform offers a range of services, including data capture, cleaning, and analysis, alongside features for content sharing and project management. By leveraging internet technology, Naxions aims to support pharmaceutical enterprises in developing their brand image and increasing market awareness through real-time data analysis and visualization.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Prescryptive Health, Inc. is a digital health company based in Redmond, Washington, that operates a prescription benefits platform aimed at enhancing accessibility, affordability, and personalization in the medication market. Established in 2017, the company provides a range of services, including the analysis of existing plan designs, recommendations for new plans, and assistance with member enrollment. Its platform offers users, including employers, health plans, providers, pharmacies, and pharmaceutical companies, direct access to unbiased market pricing and essential information about prescribed treatments. This enables patients to understand their out-of-pocket expenses, insurance coverage, and available lower-cost alternatives at the point of care, thereby promoting informed decision-making in the prescription drug market.
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Adjuvance Technologies, Inc. is a biopharmaceutical company based in Lincoln, Nebraska, founded in 2009. The company specializes in the design and manufacture of adjuvant molecule vaccines, which enhance the immune response in vaccination. Its product offerings include Saponex, a synthetic version of the naturally occurring adjuvant QS-21; TQL1055, a synthesized novel analogue; and Triterpene Saponin Synthesis Technology (TriSST), which focuses on the synthesis of novel compositions. Additionally, Adjuvance provides TiterQuil, a collection of unique molecules that do not occur in nature. Through its innovative approach, Adjuvance Technologies aims to advance vaccine efficacy and contribute to public health.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Taimei Technology specializes in developing cloud-based software solutions for clinical research and pharmacovigilance, aimed at enhancing efficiency in the biopharmaceutical industry. Founded in 2013 and headquartered in Jiaxing, China, the company offers a wide array of integrated solutions, including electronic data collection, drug randomization, electronic patient-reported outcomes, and medical imaging systems. Its platform supports collaboration among sponsors, clinical sites, contract research organizations (CROs), patients, and regulatory bodies, facilitating comprehensive clinical trial management and drug monitoring. Taimei Technology also provides additional services such as training, consulting, and outsourcing, catering to the needs of pharmaceutical companies and clinical research organizations. With offices in Shanghai and Beijing, Taimei Technology is dedicated to advancing the clinical research landscape through innovative technology.
Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Allysta Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic peptides for eye diseases. The company’s products include ALY688 for treatment of inflammatory ocular surface disorders. It develops medicines for dry eye disease and liver disease. Allysta Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Belmont, California.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Retrotope Inc. is a biotechnology company that focuses on developing drugs for the treatment of degenerative and intractable diseases, particularly neurological disorders. Based in Los Altos, California, the company aims to preserve and restore mitochondrial health through a novel drug platform that targets metabolic processes linked to oxidative stress. Retrotope's portfolio includes RT001, a drug designed for infantile neuroaxonal dystrophy, and it actively works on treatments for conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. Established in 2006, Retrotope employs innovative approaches, including the isotope effect, to slow damaging biological pathways, thereby addressing various major classes of biopolymers and advancing its commitment to improving patient outcomes in degenerative diseases.
Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. The company specializes in the development of small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Through its research and development efforts, Xgene Pharmaceutical seeks to address significant medical needs in these areas.
Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.
Taimei Technology specializes in developing cloud-based software solutions for clinical research and pharmacovigilance, aimed at enhancing efficiency in the biopharmaceutical industry. Founded in 2013 and headquartered in Jiaxing, China, the company offers a wide array of integrated solutions, including electronic data collection, drug randomization, electronic patient-reported outcomes, and medical imaging systems. Its platform supports collaboration among sponsors, clinical sites, contract research organizations (CROs), patients, and regulatory bodies, facilitating comprehensive clinical trial management and drug monitoring. Taimei Technology also provides additional services such as training, consulting, and outsourcing, catering to the needs of pharmaceutical companies and clinical research organizations. With offices in Shanghai and Beijing, Taimei Technology is dedicated to advancing the clinical research landscape through innovative technology.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
The Nue Co. Ltd. specializes in the production of science-backed nutritional supplements derived from organic ingredients. Founded in 2016 and based in London, the company emphasizes simplicity and creativity, inspired by Danish principles. Its product range includes vitamins, milk protein, plant protein, magnesium, prebiotics, and probiotics, all formulated without toxic preservatives, additives, or fillers. The ingredients are responsibly sourced and clinically proven to address various health concerns, including fatigue, skin issues, inflammation, and digestive problems. The Nue Co. operates on a subscription model through its online platform, ensuring that consumers have easy access to high-quality supplements. Committed to sustainability, the company limits plastic packaging and aims to reduce its carbon footprint, while maintaining transparency and high standards in ingredient sourcing.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company focused on the Chinese market, primarily engaged in the acquisition, development, and commercialization of healthcare products. The company offers a diverse portfolio that includes dermatological and oral care products. Its dermatological offerings feature Ebernet, an eberconazole cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the oral care segment, Luqa provides Lacteol, a probiotic for infants and immunocompromised patients, and GelX, a medical device for managing oral cavity pain from conditions like mucositis and stomatitis. Other products include GelX Xero for dry mouth relief, Aftacure for oral mucosal lesions, Ialuxid Gel for post-surgical wounds, and Podofilm for benign epithelial formations. Established in 2010 and based in Central, Hong Kong, Luqa Pharmaceuticals is dedicated to enhancing patient quality of life through innovative healthcare solutions.
Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.
Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2012 and headquartered in New Taipei City, Taiwan, the company is advancing several drug candidates through clinical trials. Notably, CX-4945 is undergoing phase I/II trials for cholangiocarcinoma in combination with gemcitabine and cisplatin, while CX-5461 is being tested in phase I studies for advanced hematologic malignancies and solid tumors, including breast cancer. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and recurrent SHH medulloblastoma through pediatric brain tumor consortium studies. Senhwa Biosciences aims to identify and develop therapies that have the potential to significantly enhance treatment outcomes for patients, focusing on underexploited targets that could improve the standard of care.
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.
Indel Therapeutics Inc. is a Vancouverâ€based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficultâ€toâ€treat and hospitalâ€acquired infections. These programs are based on Indel's paradigmâ€changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance.
Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
360Guanxi (formerly eChinaChem) is an integrated media company for the Chinese chemical, pharmaceutical and life science industries.
eChinaChem, Inc. operates an online marketplace for chemical trading in China, specializing in a wide range of products including pharmaceutical raw materials, pesticides, fertilizers, coatings, and various chemical agents. The company also manages eChinaBio, a platform dedicated to life sciences and research. In addition to its marketplace, eChinaChem organizes international conferences and events for industry executives and publishes the eChinaChem Buyers' Guide, which serves as a directory for buyers seeking information on chemical and pharmaceutical producers in China. Furthermore, the company offers strategic consulting, marketing, sourcing, and contract manufacturing services. Based in Shanghai, eChinaChem is a subsidiary of Pacific Genuity, Inc.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.
Inimex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of Innate Defense Regulators (IDRs). These innovative drugs are designed to selectively modulate the body's innate immune defenses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, reduce tissue damage, and mitigate bacterial infections. Inimex's IDR products target a range of medical conditions, including infections and tissue injury-related ailments such as ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is dedicated to advancing its unique therapies to improve patient outcomes.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.